Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: improved financial metrics and gross margins are positive, but the increased operating loss and lack of specific guidance on FDA processes and German market improvements create uncertainty. The Q&A reveals cautious optimism but lacks concrete timelines and data. The absence of a new partnership or shareholder return plan further tempers any positive outlook. Therefore, the stock price is likely to remain stable in the short term.
Key Financial Performance
Full Year 2025 Sales Revenues $37.1 million, increased 4% year-over-year. Growth driven by strong performance in international markets, with direct sales outside of Germany up 13% to $8.6 million and distributor sales up 11.4% to $16.5 million. Decline in Germany sales by 10% to $11.8 million due to restructuring efforts.
Gross Margin (Full Year 2025) 71%, up from 70% in 2024. Improvement attributed to manufacturing efficiencies.
Operating Loss (Full Year 2025) $14.7 million, improved by 10% compared to $16.5 million in 2024. Improvement due to higher revenue and improved gross margin.
Adjusted Net Loss (Full Year 2025) $14.2 million or $0.23 per share, compared to $12.7 million or $0.23 per share in 2024.
Adjusted EBITDA Loss (Full Year 2025) $10.5 million, improved by 9% year-over-year.
Q4 2025 Revenue $9.2 million, increased 1% year-over-year but down 8% on a constant currency basis.
Gross Margin (Q4 2025) 74%, up from 71% in Q4 2024. Improvement due to operating efficiencies.
Operating Expenses (Q4 2025) $11.4 million, up from $10.1 million in Q4 2024. Increase due to $500,000 restructuring charge and costs related to DrugSorb application and administrative expenses.
Operating Loss (Q4 2025) $4.6 million, compared to $3.7 million in Q4 2024.
Net Loss (Q4 2025) $5.5 million or $0.09 per share, compared to $7.6 million or $0.14 per share in Q4 2024.
Adjusted Net Loss (Q4 2025) $4.3 million or $0.07 per share, compared to $1.7 million or $0.03 per share in Q4 2024. Prior year included a $1.7 million tax benefit.
Adjusted EBITDA Loss (Q4 2025) $3.2 million, compared to $2.4 million in Q4 2024.
Cash, Cash Equivalents, and Restricted Cash (End of 2025) $7.8 million, compared to $9.1 million at the end of September 2025. Decrease due to operating cash burn and increased working capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PuriFi: A stand-alone hemoperfusion pump designed to deliver CytoSorb therapy without reliance on existing dialysis infrastructure. Over 100 units have been placed globally, enabling earlier intervention and expanding access in regions with limited dialysis infrastructure.
HotSwap: A newly launched innovation simplifying and accelerating cartridge exchanges in ICUs. It minimizes blood loss during exchanges and supports more frequent cartridge changes, enhancing usability and driving adoption.
International Market Expansion: Direct sales outside of Germany increased by 13% to $8.6 million, and distributor sales grew by 11.4% to $16.5 million, accounting for 68% of total revenue.
Germany Market Restructuring: Sales in Germany declined by 10% to $11.8 million due to restructuring efforts aimed at building a scalable and execution-driven commercial organization. Early signs of improvement are visible in 2026.
Gross Margins: Gross margins improved to 71% for the full year and 74% in Q4, driven by manufacturing efficiencies.
Cost Reduction: A workforce and cost reduction program was implemented, resulting in a $500,000 restructuring charge in Q4 and a path to cash flow breakeven by the second half of 2026.
DrugSorb-ATR: Progress made with FDA regulatory process for U.S. market approval. The STAR-T trial published in a leading journal showed safety and efficacy in reducing bleeding severity in high-risk CABG patients. Initial market opportunity estimated at $300 million, expanding to over $1 billion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Decline in Germany: Sales in Germany declined by 10% to $11.8 million in 2025 due to restructuring efforts, which could impact short-term revenue and market presence.
Regulatory Challenges for DrugSorb-ATR: The initial De Novo submission for DrugSorb-ATR was denied by the FDA, requiring additional work and delaying U.S. market entry, which could impact revenue growth and market expansion.
Cash Flow and Financial Sustainability: The company reported a net operating cash burn of $3.8 million in Q4 2025, with total cash reserves at $7.8 million as of December 31, 2025. This raises concerns about financial sustainability until achieving cash flow breakeven in the second half of 2026.
Workforce and Cost Reduction Program: A $500,000 restructuring charge was incurred in Q4 2025 due to workforce and cost reduction programs, which may affect employee morale and operational efficiency.
Dependence on International Markets: While international sales outside Germany grew, the company remains heavily reliant on these markets for revenue, which could expose it to geopolitical and economic risks.
Production and Inventory Costs: Higher inventory levels in Q4 2025 increased cash burn, although these are expected to normalize in 2026. This could temporarily strain financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects consistent revenue growth in 2026, driven by international markets and a turnaround in Germany.
Germany Market Turnaround: The company anticipates gradual and sustained improvement in Germany's market performance throughout 2026, following restructuring efforts.
PuriFi System Expansion: The PuriFi system is expected to drive incremental disposable usage, improve adherence to treatment protocols, and strengthen the installed base over time.
DrugSorb-ATR FDA Approval: The company is actively working with the FDA to finalize requirements for a streamlined and targeted resubmission for DrugSorb-ATR market authorization in the U.S.
Cash Flow Breakeven: The company expects to achieve operating cash flow breakeven in the second half of 2026.
Clinical Data and Adoption: The company plans to leverage new clinical data to drive adoption and sales growth, focusing on the right patient, right time, and right dose framework.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you help us understand the FDA regulatory process timelines and guideposts over the next few months?
A:The company is in interactive discussions with the FDA to ensure alignment before submission. This approach aims to streamline the process and address FDA concerns. Updates will be provided once there is better visibility on the completion of these discussions.
Q:How confident are you about aligning with the FDA on concerns and avoiding risks of disagreement?
A:The company is working with the FDA to define a regulatory path forward, building on the appeal decision from last year. They are addressing additional details to ensure alignment and will provide updates when there is more clarity.
Q:Can you provide more details on the early signs of improvement in the German market?
A:The company implemented leadership changes and a proactive market development approach, moving away from opportunistic sales. While progress has been slower than expected, the team is embracing changes, and there is optimism about the benefits of these efforts.
Q:Are you in the later stages of restructuring efforts in the German market?
A:Yes, the organizational structure is largely in place, and incremental improvements are expected over time. The focus is now on executing the strategy, with Q1 showing positive results.
Q:Will gross margins improve beyond the current 74% in 2026?
A:The company aims to maintain gross margins in the low 70% range (71%-74%) in the near term. Opportunities for improvement exist, but they depend on factors like increased volumes.
Q:Can you elaborate on the PuriFi pump strategy and its revenue potential?
A:The strategy is similar to a printer-cartridge model, subsidizing the pump cost for future disposable revenue. Currently, the pump is not a material revenue contributor, but it is seen as an investment to drive future disposable sales, particularly in distributor countries.
Q:What steps are being taken to achieve operating breakeven by the second half of the year?
A:Headcount reductions and other cost-cutting measures initiated in Q4 are expected to yield results. The company is also optimizing production levels and managing working capital to improve cash flow efficiency.
Q:What derisking steps are being taken for the DrugSorb-ATR resubmission to the FDA?
A:The company is being cautious and conservative, ensuring alignment with the FDA to avoid surprises. They are prioritizing certainty over speed in the submission process and will update stakeholders as clarity improves.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or detailed clarity on the FDA submission process, stating only that discussions are ongoing. Additionally, while they mentioned optimism about the German market and gross margin improvements, they did not provide concrete data or projections to substantiate these claims.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CABG
Cytosorbents
Form
Germany term
ISICEM
PuriFi
STAR
access
account
activity
adoption
capital
cartridge
cash burn
challenge
charge workforce
clinician
concern
currency basis
device safety
dialysis infrastructure
engagement
exchange
focus
framework patient
increase inventory
inventory level
journal
noncash
patient dose
reduction program
requirement
restructuring charge
sale Germany
sign improvement
spend
team
utilization
workforce reduction
CTSO Transcript
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a 15% revenue growth and improved gross margins, which are positive indicators. However, the continued net loss and increased operating expenses temper the optimism. The lack of strategic initiatives and operational updates, along with regulatory risks, further contribute to a neutral sentiment. Without additional insights from the Q&A and specific market cap information, the stock price is likely to remain relatively stable in the short term.
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
Unknown3-25
The earnings call presents mixed signals: improved financial metrics and gross margins are positive, but the increased operating loss and lack of specific guidance on FDA processes and German market improvements create uncertainty. The Q&A reveals cautious optimism but lacks concrete timelines and data. The absence of a new partnership or shareholder return plan further tempers any positive outlook. Therefore, the stock price is likely to remain stable in the short term.
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows positive growth in revenue and gross margin, but challenges like FDA delays, cash flow issues, and market competition create uncertainties. The Q&A session revealed management's optimism about margin improvement and sepsis treatment expansion but lacked clarity on German sales restructuring. Given these factors, the stock is likely to experience a neutral movement in the short term, as positive financial indicators are offset by regulatory and operational challenges.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there's positive growth in product sales and improved operating losses, the regulatory setbacks and lack of clear guidance on gross margins are concerning. The Q&A section reveals management's confidence in overcoming regulatory hurdles, but the lack of specificity and delays may worry investors. The stable gross margins and improved financial metrics are offset by increased operating expenses and regulatory uncertainties, resulting in a neutral sentiment. The absence of market cap information limits the prediction's precision.
CTSO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
